NCT01775592 is a Phase 4 clinical trial of Arterakin (DHA-PPQ) in Plasmodium Falciparum, sponsored by National Institute of Malariology, Parasitology and Entomology, Vietnam.

Who is sponsoring NCT01775592?

NCT01775592 is sponsored by National Institute of Malariology, Parasitology and Entomology, Vietnam.

What drugs are being tested in NCT01775592?

Interventions in NCT01775592: Arterakin (DHA-PPQ).

What condition does NCT01775592 study?

NCT01775592 studies Plasmodium Falciparum.

Is NCT01775592 still recruiting?

NCT01775592 is currently completed. Last updated 25 January 2013.

Last reviewed 2013-01-25 · How we verify

NCT01775592

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Monitoring the Efficacy of Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Traleng Commune, Central Vietnam

Completed Phase 4 Last updated 25 January 2013

What this trial tests

Phase 4 trial testing Arterakin (DHA-PPQ) in Plasmodium Falciparum in 95 participants. Completed in 1 January 2013.

Timeline

1 September 2012

Primary endpoint
1 January 2013

1 January 2013

Quick facts

Lead sponsor	National Institute of Malariology, Parasitology and Entomology, Vietnam
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	95
Start date	1 September 2012
Primary completion	1 January 2013
Estimated completion	1 January 2013
Sites	1 location across Vietnam

Drugs / interventions tested

Arterakin (DHA-PPQ) — full drug profile →

Conditions studied

Plasmodium Falciparum — all drugs for Plasmodium Falciparum →

Sponsor

National Institute of Malariology, Parasitology and Entomology, Vietnam

Who can join

2 Months and older, any sex, with Plasmodium Falciparum. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Parasite clearance time
Time frame: Day 2-5

Sponsor's own description

Resistance of Plasmodium falciparum toward Artemisinins, the most important drug for the successful treatment of malaria, has been confirmed in Cambodia. There are few reports from neighbouring countries about delayed parasite rates. The investigators therefore aim to assess parasite clearance in malaria patients in central Vietnam when treated according to national standard guidelines.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam.
Thriemer K, Hong NV, Rosanas-Urgell A, Phuc BQ, et al · · 2014 · cited 85× · PMID 25224002 · DOI 10.1128/aac.02746-14
Molecular surveillance of Plasmodium falciparum drug-resistance markers in Vietnam using multiplex amplicon sequencing (2000-2016).
Rovira-Vallbona E, Kattenberg JH, Hong NV, Guetens P, et al · · 2023 · cited 11× · PMID 37626131 · DOI 10.1038/s41598-023-40935-7

Verify or expand the search:

Other recruiting trials for Plasmodium Falciparum

Currently open trials in the same condition.

NCT06923592 — Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01775592 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Malariology, Parasitology and Entomology, Vietnam
Last refreshed: 25 January 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01775592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing